Company Filing History:
Years Active: 1995-1999
Title: David E. Trentham: Innovator in Autoimmune Treatment
Introduction
David E. Trentham is a notable inventor based in North Quincy, MA, who has made significant contributions to the field of autoimmune disease treatment. With a total of five patents to his name, he has focused on innovative methods to address rheumatoid arthritis, a debilitating condition affecting many individuals.
Latest Patents
Trentham's latest patents include a groundbreaking method of treating rheumatoid arthritis with low-dose type II collagen. This method involves the oral administration of between about 5 and 25 micrograms per day of type II collagen, aimed at suppressing the autoimmune response in afflicted joints. Another significant patent is directed towards a method and pharmaceutical formulations for treating autoimmune arthritis in mammals, including humans, through the oral, enteral, or inhalation administration of whole collagen protein or biologically active peptide fragments of collagen.
Career Highlights
Throughout his career, Trentham has been associated with Autoimmune Inc., where he has worked diligently to develop and refine his innovative treatments. His research has been pivotal in advancing the understanding and management of autoimmune diseases, particularly rheumatoid arthritis.
Collaborations
Trentham has collaborated with esteemed colleagues in the field, including Howard L. Weiner and David A. Hafler. These partnerships have fostered a collaborative environment that enhances the research and development of effective treatments for autoimmune conditions.
Conclusion
David E. Trentham's contributions to the field of autoimmune disease treatment through his innovative patents and collaborations highlight his commitment to improving patient outcomes. His work continues to pave the way for advancements in the management of rheumatoid arthritis and similar conditions.